X4 Pharmaceuticals Stock Alpha and Beta Analysis
| XFOR Stock | USD 0.44 0.01 2.22% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as X4 Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in X4 Pharmaceuticals over a specified time horizon. Remember, high X4 Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to X4 Pharmaceuticals' market risk premium analysis include:
Beta (1.83) | Alpha 0.88 | Risk 12.58 | Sharpe Ratio 0.0704 | Expected Return 0.89 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
XFOR |
X4 Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. X4 Pharmaceuticals market risk premium is the additional return an investor will receive from holding X4 Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in X4 Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate X4 Pharmaceuticals' performance over market.| α | 0.88 | β | -1.83 |
X4 Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of X4 Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how X4 Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.X4 Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how X4 Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading X4 Pharmaceuticals shares will generate the highest return on investment. By understating and applying X4 Pharmaceuticals stock market price indicators, traders can identify X4 Pharmaceuticals position entry and exit signals to maximize returns.
X4 Pharmaceuticals Return and Market Media
The median price of X4 Pharmaceuticals for the period between Thu, Nov 28, 2024 and Wed, Feb 26, 2025 is 0.51 with a coefficient of variation of 24.59. The daily time series for the period is distributed with a sample standard deviation of 0.13, arithmetic mean of 0.54, and mean deviation of 0.11. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 1578 shares by Mary DiBiase of X4 Pharmaceuticals subject to Rule 16b-3 | 01/16/2025 |
2 | Acquisition by Arbet-engels Christophe of 25831 shares of X4 Pharmaceuticals subject to Rule 16b-3 | 01/23/2025 |
3 | X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application for Mavorixafor for the Treatment of WHIM Syndrome | 01/24/2025 |
4 | X4 Pharmaceuticals, Inc. COO Mary Dibiase Sells 22,258 Shares | 01/28/2025 |
5 | X4 Pharmaceuticals CFO Mostafa Adam S. sells 33,946 in stock - MSN | 01/30/2025 |
6 | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 02/03/2025 |
7 | X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity ... | 02/06/2025 |
8 | X4 Pharmaceuticals Buy Rating Reaffirmed at HC Wainwright - MarketBeat | 02/11/2025 |
9 | X4 pharmaceuticals chief commercial officer Mark Baldry acquires 19,251 in stock - MSN | 02/14/2025 |
10 | X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI in WHIM Syndrome in Select Middle East Cou... | 02/19/2025 |
About X4 Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including XFOR or other stocks. Alpha measures the amount that position in X4 Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Graham Number | 2.21 | 2.1 | Receivables Turnover | 2.94 | 1.8 |
X4 Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of X4 Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, X4 Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of X4 Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of X4 Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of X4 Pharmaceuticals' management manipulating its earnings.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with X4 Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.